PLEASANTON, Calif., Sept. 11, 2012 /PRNewswire/ -- Thoratec Corporation (NASDAQ: THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, said today it will be participating in two upcoming investor conferences.
On Thursday, September 13, the company will participate in the ThinkEquity 9 th Annual Growth Conference. Taylor C. Harris, Senior Director of Investor Relations and Business Development, will provide an update on the company beginning at 2:30 p.m., Eastern Daylight Time ( 11:30 a.m., Pacific Daylight Time). The presentation will be available through the conference web site at http://wsw.com/webcast/tep22/thor/ , or on the company's web site at http://www.thoratec.com.
On Wednesday, September 19, Thoratec will participate in the UBS 2012 Global Life Sciences Conference. The presentation by Taylor C. Harris, Senior Director of Investor Relations and Business Development, will begin at 8:30 a.m., Eastern Daylight Time ( 5:30 a.m., Pacific Daylight Time). The presentation will be available through the conference web site at http://cc.talkpoint.com/ubsx001/091912a_im/?entity=55_7YKIS01 , or on the company's web site at http://www.thoratec.com.
Thoratec is a world leader in therapies to address advanced-stage heart failure. The company's products include the HeartMate® LVAS (Left Ventricular Assist System) and Thoratec® VAD (Ventricular Assist Device) with more than 20,000 devices implanted in patients suffering from heart failure. Thoratec also manufactures and distributes the CentriMag® and PediMag®/PediVAS® product lines. Thoratec is headquartered in Pleasanton, California. For more information, visit the company's web site at http://www.thoratec.com.Thoratec, the Thoratec logo, HeartMate, HeartMate II and GoGear are registered trademarks of Thoratec Corporation. CentriMag and PediMag are registered trademarks of Thoratec LLC, and PediVAS is a registered trademark of Thoratec Switzerland GmbH.